| Ticker: | ACIU |
| Current Price: | $2.13 |
| % Daily Change: | -0.47% |
| Volume (1,000s): | 114.78 |
| Average Volume (1,000s): | 276.39 |
| Market Cap (M): | $216.78 |
| 1/2/2024 Price: | $4.69 |
| Change Since Inception: | -54.58% |
AC Immune SA
Building B
EPFL Innovation Park
Lausanne 1015
Switzerland
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.